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Aged P65 yearsa b s t r a c t
The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for all aged P65 years in
the UK to help reduce the burden of invasive pneumococcal disease (IPD). A total of 728 IPD cases aged
P65 years were diagnosed between 1 April 2006 and 31 July 2012 in the North East of England. Crude
vaccine effectiveness (VE) estimates for PPV23 were calculated using the indirect-cohort method using
a stratiﬁed analysis. VE for persons aged P65 years was 28.5% (95% conﬁdence interval: 17.4%,
56.5%). PPV23 was less effective in older age groups at IPD diagnosis and for those vaccinated at an older
age. Estimates of VE published since the introduction of PPV23 appear to show a decrease in VE over time,
possibly due to changes in demographics, circulating serotypes and vaccine formulation. An effective
PPV23 vaccination programme should continue in those aged P65 years in the North East of England.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Invasive pneumococcal disease (IPD) is a considerable cause of
morbidity and mortality in the UK with approximately 5000–
6000 cases of IPD reported annually to the Health Protection
Agency (HPA) [1]. Although the incidence of IPD in the North East
region of England decreased from 11.9 to 9.7 cases per 100,000
population from 2006–07 to 2009–10, the case-fatality ratio was
unchanged at 19% [2]. In order to reduce the number of IPD cases
in the UK population a 23-valent pneumococcal polysaccharide
vaccine (PPV23) has been recommended for all individuals aged
P65 years since April 2005, as well as for all high risk individuals
agedP2 years since 2003. Routine revaccination with PPV23 is not
recommended for individuals agedP65 years in the UK [3]. PPV23
protects against 23 of the most common pneumococcal serotypes,yet the effectiveness of PPV23 in reducing IPD incidence in high
risk adults and those aged P65 remains uncertain [4–7]. Mooney
et al. [7] found that PPV23 vaccination was signiﬁcantly effective
in adults aged P65 years, whereas Huss et al. [4] failed to ﬁnd
evidence of statistically signiﬁcant vaccine protection in a meta-
analysis of clinical trials. PPV23 uptake in those aged P65 years
in the North East of England was approximately 70% by 31 March
2012. It is important to investigate vaccine effectiveness (VE) of
PPV23 since efforts to increase PPV23 uptake could be undertaken
in order to reduce the burden of IPD in the older population. This
study provides VE estimates of PPV23 in IPD cases agedP65 years
diagnosed from 1 April 2006 to 31 July 2012 in the North East of
England.
2. Patients and methods
2.1. Regional enhanced surveillance of IPD
In April 2006 an IPD enhanced surveillance system (IPDESS) was
established by the HPA North East to capture all cases of IPD,
deﬁned as Streptococcus pneumoniae isolated from a normally
sterile site (e.g. blood, cerebrospinal, pleural ﬂuid) along with a
clinical diagnosis of invasive disease (e.g. bacteraemic pneumonia,
meningitis, septicaemia) residing in the North East of England [2].
This study included cases ascertained by IPDESS aged P65 years
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Isolates of S. pneumoniae were serotyped at the HPA Respiratory
and Systemic Infection Laboratory. Age and date at IPD diagnosis,
sex, PPV23 vaccination status, date of vaccination, underlying risk
factors [3] and serotype were obtained from IPDESS. Cases that
received PPV23 vaccination after their reported date of IPD diagno-
sis were treated as non-vaccinated cases. Where >1 episode of IPD
was recorded, only the ﬁrst episode was included in the analysis.
Three cases received >1 dose of PPV23 before ﬁrst IPD diagnosis;
for age at vaccination analyses the ﬁrst vaccination was used,
and for time since vaccination analyses the last vaccination was
used. We estimate that approximately 20% of our cases were also
included in another recent study [6].
2.2. Statistical analysis
For infections where vaccination provides protection against
certain serotypes but not against others, VE can be estimated usingTable 1
Characteristics of IPD cases diagnosed between 1 April 2006 and 31 July 2012 in the Nort
Variable Categories Nu
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PPV23 vaccination status Vaccinated 36
Non-vaccinated 16
Unknown 25
Time since vaccinationa 0–4 years 80
5–9 years 12
P10 years 92
Age at vaccinationb <65 years 50
65–74 years 14
P75 years 10









Other PPV23 serotypes 24










5 (Most deprived) 14
Unknown 18
a Years between PPV23 vaccination and IPD diagnosis. Date of last vaccination is used
b Age at ﬁrst vaccination is used for cases (n = 3) who had received >1 dose of PPV23
c Includes those IPD cases diagnosed with either one of: chronic heart disease, chronic l
leak(s).
d Includes those IPD cases diagnosed with either one of: chronic renal disease, immu
e The ﬁve PPV23 serotypes that accounted for the most vaccine type IPD cases; rema
given as the number of cases of that vaccine type serotype out of the total 555 vaccine
f Epidemiological year of IPD diagnosis includes cases from 1 April to 31 March inclus
2011 to 31 July 2012.
g Index of multiple deprivation (IMD) 2010 quintiles based on quintiles for lower supthe indirect cohort method [8]. This method compares individuals
infected with serotypes covered by the vaccine (vaccine-type, VT)
with those infected with serotypes not covered by the vaccine
(non-vaccine-type, NVT) using a case-control study design. For
vaccination with PPV23, this corresponds to a comparison of indi-
viduals infected with S. pneumoniae serotypes covered by PPV23
with those individuals infected with S. pneumoniae serotypes not
covered by PPV23. The main assumption of this method is that
those individuals vaccinated with PPV23 have the same risk of
infection from non-PPV23 serotypes as unvaccinated individuals,
i.e. vaccination with PPV23 confers no immunity against NVT ser-
otypes. VE is calculated as VE (%) = (1  OR)  100, where OR is the
odds of an individual being vaccinated and diagnosed with VT IPD
compared to the odds of an individual being vaccinated and diag-
nosed with NVT IPD. We estimated crude VE of PPV23 for each age
group (65–74, 75–84,P85 andP65 years) and performed a strat-
iﬁed analysis by age at diagnosis, sex, time since vaccination, age at
vaccination, risk factors for IPD, serotype, year of diagnosis andh East of England.
mbers of IPD cases
ccine type (%) Non-vaccine type (%) All cases
0 (83.7) 39 (16.3) 239
8 (83.8) 44 (16.2) 272
7 (84.7) 23 (15.3) 150
5 (84.0) 106 (16.0) 661
0 (85.5) 44 (14.5) 304
5 (82.6) 62 (17.4) 357
3 (83.3) 73 (16.7) 436
7 (87.4) 24 (12.6) 191
(73.5) 9 (26.5) 34
(84.2) 15 (15.8) 95
7 (78.9) 34 (21.1) 161
(85.2) 16 (14.8) 108
(82.0) 11 (18.0) 61
1 (79.2) 37 (20.8) 178
8 (86.4) 17 (13.6) 125
6 (85.0) 24 (15.0) 160
4 (84.7) 64 (15.3) 418
0 (83.3) 34 (16.7) 204






9 (44.9) – 249
3 (85.8) 17 (14.2) 120
(89.0) 11 (11.0) 100
(89.0) 11 (11.0) 100
(84.0) 16 (16.0) 100
(78.4) 24 (21.6) 111
1 (80.8) 24 (19.2) 125
(91.7) 7 (8.3) 84
4 (81.9) 23 (18.1) 127
6 (89.1) 13 (10.9) 119
5 (76.1) 33 (23.9) 138
5 (85.3) 25 (14.7) 170
(78.3) 5 (21.9) 23
for cases (n = 3) who had received >1 dose of PPV23 before ﬁrst IPD diagnosis.
before ﬁrst IPD diagnosis.
ung disease, chronic liver disease, diabetes, previous IPD, cochlear implant(s) or CSF
nosuppression or asplenia/dysfunction of the spleen.
ining serotypes grouped into one category due to small numbers. Percentages are
type IPD cases.
ive, with the exception of epidemiological year 2011–12 which spans from 1 April
er output areas in the North East region of England [18].
L.B. Wright et al. / Trials in Vaccinology 2 (2013) 45–48 47deprivation. Corresponding 95% conﬁdence intervals (CI) were
calculated and all tests were two tailed with a p-value <0.05
considered statistically signiﬁcant. To assess the extent of con-
founding of crude VE estimates, logistic regression was used and
the percentage changes from the crude, unadjusted VE estimate
were recorded. All analyses were performed using STATA version
12.0 (Stata Corp, Texas).3. Results
The numbers, percentages and distribution of IPD cases are de-
tailed in Table 1. Only three cases received >1 dose of PPV23. In to-
tal there were 728 cases of IPD aged P65 years, of which 67 were
un-typed. Of the 661 typed cases used in the analyses, 555 (84%)
were diagnosed with VT IPD whilst 106 (16%) were diagnosed with
NVT IPD. Of all 661 typed cases, 436 (66%) had been vaccinated
with PPV23 prior to IPD diagnosis; vaccination status was un-
known for 34 cases. There was no signiﬁcant difference in age at
diagnosis, years since vaccination and age at vaccination between
VT and NVT cases (results not shown). The overall VE of PPV23
for those aged P65 years was 28.5% (95% CI: 17.4%, 56.5%),
although this was not statistically signiﬁcant (Table 2). Crude
estimates of VE for the study age groups suggest a decline in VE
with age at diagnosis. However, stratiﬁcation by time since
PPV23 vaccination did not show a clear relationship with VE. Those
vaccinated 5–9 years prior to IPD diagnosis seemed to experience
greater protection, particularly in those aged 75–84 at diagnosis,
although this may be due to the small number of cases across
strata. A comparison of VE for those vaccinated between the ageTable 2
PPV23 vaccine effectiveness estimates by age group at IPD diagnosis according to sex, time s
year of IPD diagnosis, area of residence and index of multiple deprivation quintile.
Variable Categories Age at IPD diagnosis (% VE, 95%
65–74 years
Overall VE 43.6 (27.1, 74.9)
Sex Male 21.4 (133.4, 73.6)
Female 61.3 (42.8, 89.5)
Time since vaccination 0–4 years 55.2 (18.6, 82.8)
5–9 years 48.1 (350.6, 46.1)
P10 years 11.1 (391.0, 67.5)
Age at vaccination <65 years 6.1 (153.1, 63.7)
65–74 years 25.0 (92.6, 70.7)
P75 years -
Risk factors for IPD No known risk factor 237.5 (1820.5, 40.7)
Immunocompetent 70.3 (6.2, 91.7)
Immunocompromised 40.8 (109.9, 83.3)
Serotype 1 30.8 (154.5, 80.8)
3 45.6 (121.5, 86.2)
7F 46.2 (94.3, 85.0)
19A 61.9 (38.9, 89.6)
22F 23.8 (260.3, 82.3)
All other serotypes 43.0 (44.9, 79.0)
Year of IPD diagnosis 2006–07 57.6 (148.3, 92.8)
2007–08 50.0 (1114.7, 81.5)
2008–09 
2009–10 58.3 (317.8, 95.8)
2010–11 15.0 (325.6, 83.0)
2011–12 76.9 (105.3, 97.4)
IMD quintile 1 (Least deprived) -
2 1640.0 (20147.0, 49.5)*
3 80.3 (95.6, 98.0)
4 23.6 (231.0, 82.4)
5 (Most deprived) 71.7 (46.8, 94.6)
-Unable to estimate VE since all VT or all NVT cases were vaccinated.
-Unable to estimate VE since no VT or no NVT cases were vaccinated.
* Signiﬁcant at 5% level.of 65–74 years and those vaccinated when aged P75 years sug-
gests a substantially reduced VE for the older age group (where
VE fell below zero). PPV23 vaccination appears to be more effective
for those aged P65 years with underlying conditions associated
with an increased risk of IPD than in those without, with similarly
good protection for immunocompetent and immunocompromised
cases. However, a lack of power may have contributed to these
non-signiﬁcant estimates. Adjustment for potential confounding
variables made little difference to the VE estimate when compared
to the crude estimate (results not shown).4. Discussion
Our crude VE estimate of PPV23 for those aged P65 years of
28.5% (95% CI: 17.4%, 56.5%) is very close to that estimated by a
recent study in England and Wales of 24% (95% CI: 10%, 36%) [6],
and supports the ﬁnding that PPV23 is moderately effective in pre-
venting IPD inP65 year olds. Our study suggests that PPV23 is less
effective for those who receive PPV23 vaccination aged P75 years
compared to those aged 65–74 years. This may be explained by the
apparent inability of older adults to mount a full immune response
to PPV23 [9], and supports the suggestion that the younger an
individual, the greater their immune response will be to pneumo-
coccal vaccination [10]. Receiving multiple doses of PPV23 has
been associated with hyporesponsiveness in adults [11], however
since only three individuals received >1 dose this was not a factor
in this study. Results of a Cochrane review [12] of observational
PPV23 VE studies conducted between 1978 and 2005 for IPD cases
P55 years found the VE of PPV23 to be 35–70%. The older studiesince PPV23 vaccination, age at PPV23 vaccination, risk factors for IPD, PPV23 serotype,
conﬁdence intervals)
75–84 years P85 years All aged P65
21.1 (75.1, 64.5) 7.5 (159.3, 67.0) 28.5 (17.4, 56.5)
44.5 (107.0, 85.1) - 44.8 (21.2, 74.8)
0.4 (176.7, 63.6) 60.2 (418.0, 50.4) 13.1 (65.5, 54.3)
165.6 (1335.2, 24.9) - 9.3 (119.0, 42.6)
64.7 (18.8, 85.0)* 48.1 (93.6, 86.0) 38.3 (6.2, 64.0)
21.8 (257.7, 53.2) 15.2 (377.9, 68.8) 20.9 (137.1, 35.4)
23.1 (5734.9, 85.8) - 10.0 (102.8, 56.8)
51.2 (13.5, 79.9) 16.7 (776.5, 85.2) 38.2 (5.8, 63.9)
42.9 (317.1, 44.8) 32.6 (428.0, 72.8) 39.5 (168.0, 24.3)
32.5 (305.6, 88.8) 36.0 (178.3, 85.3) 16.7 (188.1, 52.8)
18.8 (219.9, 55.9) 5.0 (394.9, 81.8) 32.4 (35.6, 66.4)
33.3 (233.9, 86.7) 28.6 (615.9, 92.9) 33.0 (64.9, 72.8)
57.1 (72.3, 88.9) 40.0 (250.0, 89.3) 44.1 (22.8, 74.3)
77.3 (771.7, 57.1) 0.0 (706.0, 85.0) 3.3 (140.1, 54.3)
45.5 (87.6, 84.0) 28.6 (260.2, 85.8) 42.5 (20.5, 72.5)
36.4 (163.0, 83.5) 628.6 (35335.1, 28.8) 18.8 (81.1, 63.0)
3.6 (353.6, 73.7) 3.6 (503.8, 83.1) 8.4 (114.6, 59.9)
19.3 (103.8, 70.2) 27.8 (144.6, 80.6) 31.7 (19.6, 61.8)
250.0 (1909.7, 39.0) 57.1 (2840.9, 91.6) 25.5 (282.2, 58.8)
65.0 (235.8, 96.4) - 35.5 (160.5, 84.1)
33.3 (1556.7, 89.3) - 69.6 (157.3, 96.4)
53.1 (349.7, 95.1) 460.0 (7504.9, 58.8) 20.8 (170.3, 76.8)
35.0 (733.0, 78.1) 6.7 (523.0, 86.0) 4.1 (185.6, 62.1)
70.9 (154.0, 96.7) 70.0 (2187.3, 87.4) 62.8 (34.7, 89.7)
- - -
23.5 (247.8, 83.2) 90.0 (940.4, 65.3) 98.2 (421.6, 24.7)
143.8 (1465.9, 62.1) - 35.3 (154.8, 83.6)
78.2 (92.2, 97.5) 43.8 (486.4, 94.6) 51.7 (38.4, 83.2)
10.0 (369.2, 74.2) - 23.7 (97.9, 70.5)
48 L.B. Wright et al. / Trials in Vaccinology 2 (2013) 45–48[13,14] in the review contributed higher estimates of VE. The study
by Andrews et al. [6] found VE to be 24%, similar to our estimate,
which overlaps only with the latter period of the Cochrane review.
This apparent decrease in VE for PPV23 over timemay be explained
by demographic changes within the population aged P65 years
(with a higher proportion living longer) or by the effect of herd-
immunity on serotype distribution following the introduction of
PCV7 and PCV13 in the UK routine childhood vaccination program
[15]. Any formulation differences of PPV23 vaccines over time and
the differences in study population and methodology in previous
studies are also possible explanations for the apparent decrease
in VE over time. The major limitation of this study is the low num-
ber of NVT cases relative to VT cases. This has unavoidably led to a
low power for this study compared to larger studies [6], a common
limitation with studies of relatively small populations [16,17].
However, the statistical signiﬁcance of the ﬁndings should not
negate the potential public health implications. The population
aged P65 years is at high risk of IPD and under these circum-
stances the consideration that should be given to a 95% CI versus
clinical signiﬁcance is not clear. Moreover, this study has major
strengths. In particular, the contemporaneous collection of data
on all conﬁrmed IPD cases throughout the study period and across
the region makes the VE estimates representative of the entire
population of the North East of England aged P65 years. This
completeness together with the prospective methodology for data
capture used ensures that very little bias has been introduced. We
believe that an effective PPV23 vaccination programme should
continue to target vaccination of individuals shortly after they turn
65 years of age in the North East of England.Disclosure statement
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